Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04361058
Title Nivolumab for High-Risk MDS/AML Patients After Allogeneic Stem Cell Transplant With Post-Transplant Cyclophosphamide
Recruitment Withdrawn
Gender both
Phase Phase I
Variant Requirements No
Sponsors SCRI Development Innovations, LLC
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.